Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …

To evaluate these risks, we enrolled 200 patient-facing HCWs between March 26 and April 8,
2020, in SARS-CoV-2 Acquisition in Frontline Healthcare Workers—Evaluation to inform …

Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …

We sought to compare neutralising antibody responses between seronaive haemodialysis
patients and the healthy individuals we have already reported on as part of the Legacy study. …

Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et al.,
2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. …

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the
prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. …

Patients with blood cancer continue to have a greater risk of inadequate immune responses
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …

To the Editor—The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
1–3 has led to a pandemic infecting more than seven million people worldwide in …

Most patients with blood cancer have reduced humoral and cellular immunity against SARS-CoV-2
variants following COVID-19 vaccination 1, 2, so are at increased risk of severe …

In this cohort study, we aim to compare outcomes from coronavirus disease 2019 (COVID-19)
in people with severe epilepsy and other co-morbidities living in long-term care facilities …